A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)

A Multicenter, Open-Label, Postmarketing Surveillance Study of Tofersen (BIIB067) in Adults With Amyotrophic Lateral Sclerosis (ALS) Associated With a Mutation in the Superoxide Dismutase 1 (SOD1) Gene in China

In this study, researchers will learn more about the safety of tofersen, also known as Qalsody®. This is a drug available for doctors to prescribe for people with a certain type of amyotrophic lateral sclerosis, also known as ALS. This type is in people who have a mutation in the superoxide dismutase 1 gene, also known as SOD-1.

This is known as a "postmarketing" study. In this kind of the study, the goal is to learn more about how a drug works after it has been approved for use in the general public. Tofersen was approved in China in September 2024. The main goal of this study is to collect long-term safety information in Chinese participants with SOD-1 ALS.

The main question researchers want to answer in this study is:

• How many participants have adverse events (AEs) and serious adverse events (SAEs)?

An AE is a health problem that may or may not be caused by a drug during the study. An AE is considered serious when it results in death, is life-threatening, causes lasting problems, or requires hospital care.

Researchers will also learn more about :

• How the body processes tofersen.
• How much tofersen is found in the cerebrospinal fluid (CSF), or the fluid that surrounds the brain and the spinal cord.

This study will be done as follows:

• Participants will be screened to check if they can join the study. The screening period will be up to 4 weeks.
• After joining the study, participants will receive the first 3 doses of 100 milligrams (mg) of tofersen about 14 days apart. This will be given through an intrathecal (IT) injection. This means it will be given into the fluid surrounding the spine.
• After that, participants will receive 10 more doses every 28 days through IT injections. Participants will have up to 13 total doses of tofersen in this study.
• Participants will have up to 15 visits to their study research center. Each participant will be in the study for up to 52 weeks (1 year).

Study Overview

• Status: Recruiting
• Conditions: Amyotrophic Lateral Sclerosis
• Intervention / Treatment: Drug: Tofersen

Detailed Description

The primary objective of this study is to evaluate the safety of tofersen in participants with SOD1-ALS in post marketing setting in China.

The secondary objective of this study is to evaluate the pharmacokinetics (PK) of tofersen in participants with SOD1-ALS in the postmarketing setting in China.

• Study Type: Interventional
• Enrollment (Estimated): 12
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: US Biogen Clinical Trial Center; Phone Number: 866-633-4636; Email: clinicaltrials@biogen.com
• Study Contact Backup: Name: Global Biogen Clinical Trial Center; Email: clinicaltrials@biogen.com

Study Locations

• China
  • Beijing Municipality
    • Beijing, Beijing Municipality, China, 100083
      • Recruiting
      • Peking University Third Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Key Inclusion Criteria:

• Age ≥ 18 years at the time of informed consent.
• Must have diagnosis of SOD1-ALS.
• If taking riluzole, participant must be on a stable dose for ≥ 30 days prior to Day 1 and expected to remain at that dose until the final study visit.
• If taking edaravone, participant must have initiated edaravone ≥ 60 days (2 treatment cycles) prior to Day 1 and expected to remain at that dose until the final study visit, unless the Investigator determines that edaravone should be discontinued for medical reasons, in which case it may not be restarted during the study.
• All women of childbearing potential must practice effective contraception during the study.

Key Exclusion Criteria:

• Hypersensitivity to the active substance or any of the excipients of tofersen injection.
• Current or past administration of tofersen injection, in either a commercial or a clinical study setting.
• Prior or current treatment with small interfering ribonucleic acid (RNA), stem cell therapy, or gene therapy.
• Treatment with another investigational drug, biological agent, or device within 1 month or 5 half-lives of study agent, whichever is longer, prior the Baseline Visit.
• Participants who are pregnant or currently breastfeeding, and those intending to become pregnant during the study.

Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Tofersen 100 milligrams (mg); Participants will receive tofersen 100 mg by intrathecal (IT) injection as 3 loading doses once every 2 weeks (Days 1, 15, and 29), followed by 10 maintenance doses once every 4 weeks (approximately every 28 days), for a maximum total of 13 doses per participant over a 44- week treatment period.	Drug: Tofersen; Administered by IT injection.; Other Names: BIIB067, QALSODY

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)	From Screening up to end of study follow-up (up to 52 weeks)

Secondary Outcome Measures

Outcome Measure	Time Frame
Maximum Observed Plasma Concentration (Cmax) of Tofersen	Predose and at multiple timepoints postdose on Day 1
Time to Reach Maximum Plasma Concentration (Tmax) of Tofersen	Predose and at multiple timepoints postdose on Day 1
Area Under the Concentration-Time Curve (AUC) of Tofersen in Plasma	Predose and at multiple timepoints postdose on Day 1
Tofersen Cerebrospinal Fluid (CSF) Concentration	Up to 44 weeks

Collaborators and Investigators

• Sponsor: Biogen
• Investigators: Study Chair: Medical Director, Biogen

Study record dates

Study Major Dates

• Study Start (Actual): December 11, 2025
• Primary Completion (Estimated): December 16, 2027
• Study Completion (Estimated): December 16, 2027

Study Registration Dates

• First Submitted: October 31, 2025
• First Submitted That Met QC Criteria: October 31, 2025
• First Posted (Estimated): November 3, 2025

Study Record Updates

• Last Update Posted (Actual): January 20, 2026
• Last Update Submitted That Met QC Criteria: January 16, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Central Nervous System Diseases; Nervous System Diseases; Neuromuscular Diseases; Metabolic Diseases; Neurodegenerative Diseases; Spinal Cord Diseases; TDP-43 Proteinopathies; Proteostasis Deficiencies; Motor Neuron Disease; Nutritional and Metabolic Diseases; Amyotrophic Lateral Sclerosis; tofersen
• Other Study ID Numbers: 233AS402

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No